Y0000550
峰鉴别用舒巴坦
European Pharmacopoeia (EP) Reference Standard
别名:
舒巴坦酸, (2S,5R)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸4,4-二氧化物, CP 45899, CP-45,899, 舒巴克坦, 青霉烷砜酸, 青霉酸1,1-二氧化物, 青霉酸二氧化物, 青霉酸砜
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C8H11NO5S
CAS号:
分子量:
233.24
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
sulbactam
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
2-8°C
SMILES 字串
CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O
InChI
1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1
InChI 密鑰
FKENQMMABCRJMK-RITPCOANSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Sulbactam for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Danger
危險聲明
危險分類
Resp. Sens. 1 - Skin Sens. 1
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Shu Xia et al.
PloS one, 9(7), e100707-e100707 (2014-07-02)
To investigate CTX-M genotypes among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) isolated from patients with community-onset and hospital-onset infections in China, their clonality and the distribution of CTX-M variants in different specimens of community-onset and hospital-onset infections. ESBL-EC isolates were collected
A S Levin
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 8(3), 144-153 (2002-05-16)
Recent studies have highlighted the emergence of infections involving multiresistant Acinetobacter clinical isolates. Sulbactam offers direct antimicrobial activity against Acinetobacter species. Accordingly, co-administration of sulbactam with ampicillin or cefoperazone offers the potential of effective empirical therapy against Acinetobacter and other
M Akova
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 14 Suppl 1, 185-188 (2007-12-25)
Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against beta-lactamase-producing bacteria is restored. One of the particular advantages of
J D Williams
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 24(3), 494-497 (1997-03-01)
beta-Lactamase inhibitors such as sulbactam are beta-lactam compounds that have low antimicrobial activity but are able to inhibit enzymes (beta-lactamases) that destroy beta-lactam antibiotics like penicillins and cephalosporins. The main activity of beta-lactamase inhibitors is directed against plasmid-mediated transferable enzymes
G S Singh
Mini reviews in medicinal chemistry, 4(1), 93-109 (2004-02-03)
Beta-lactam ring-containing compounds such as penicillins, ampicillin, amoxicillin, cephalosporins and carbapenems are among the most famous antibiotics. This article reviews the recent developments in study of cephems, oxacephems, penams and sulbactam. Many of the compounds reviewed have potential antibacterial activity
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门